佛慈制药(002644) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥137,964,409.24, a decrease of 11.58% compared to ¥156,036,971.07 in the same period last year[8] - Net profit attributable to shareholders increased by 2.52% to ¥13,304,999.19 from ¥12,977,405.41 year-on-year[8] - Basic earnings per share rose by 2.76% to ¥0.0261 from ¥0.0254 in the same period last year[8] - The net profit for the period was CNY 15,788,438.48, compared to CNY 15,275,829.70 in the previous period, showing a slight increase[40] - The total profit for the first quarter was CNY 15,562,888.35, slightly up from CNY 15,397,239.00 in the previous year[41] - The total comprehensive income for the first quarter was CNY 13,229,064.91, compared to CNY 12,977,405.41 in the previous year, indicating a growth of about 1.9%[42] Cash Flow - The net cash flow from operating activities surged by 319.75%, reaching ¥13,886,124.13, compared to a negative cash flow of -¥6,319,048.13 in the previous year[8] - Net cash flow from operating activities improved by 319.75% to ¥13,886,124.13, driven by higher cash receipts from sales[17] - The net cash flow from operating activities for the first quarter was ¥16,183,372.70, compared to a negative cash flow of ¥11,291,923.24 in the same period last year, indicating a significant improvement[51] - Total cash inflow from operating activities was ¥157,188,250.06, up from ¥116,316,873.02 year-over-year, reflecting a growth of approximately 35.2%[51] - The cash outflow for operating activities was ¥141,004,877.36, compared to ¥127,608,796.26 in the previous year, representing an increase of about 10.5%[51] - The company experienced a net cash inflow from other operating activities of CNY 18,736,456.43, compared to CNY 6,476,436.78 in the previous year[46] Assets and Liabilities - Total assets at the end of the reporting period increased by 1.84% to ¥2,357,476,495.56 from ¥2,314,892,098.40 at the end of the previous year[8] - Total assets as of March 31, 2020, amounted to ¥2,357,476,495.56, an increase from ¥2,314,892,098.40 at the end of 2019[31] - Total liabilities increased to CNY 801,241,014.25 from CNY 778,456,681.13, reflecting a rise in financial obligations[37] - Owner's equity rose to CNY 1,520,951,341.57 from CNY 1,509,028,563.69, indicating a strengthening financial position[37] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,535[11] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of the shares, with 90,000,000 shares pledged[11] Research and Development - R&D expenses rose by 68.48% to ¥6,409,579.19, reflecting increased investment in research and development[16] - Research and development expenses increased to CNY 6,409,579.19 from CNY 3,804,383.56, reflecting a growth of approximately 68.3%[43] Operating Costs - Total operating costs decreased to CNY 127,705,078.84 from CNY 144,831,194.22, with operating costs specifically dropping from CNY 119,784,350.28 to CNY 100,643,955.48[40] - The company reported a decrease in operating costs to CNY 64,229,060.21 from CNY 81,259,383.14, a reduction of approximately 21%[43] Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥4,506,653.76 for the period[9] - The company experienced a 133.39% increase in advance receipts, totaling ¥31,312,048.43 compared to ¥13,416,092.95 at the beginning of the period[15] - Asset disposal gains surged by 611.82% to ¥220,909.81, attributed to increased sales of fixed assets[16] - Cash inflow from financing activities was ¥9,282,733.40, with cash outflow totaling ¥14,552,406.01, resulting in a net cash flow of -¥5,269,672.61 for financing activities[49] Audit and Standards - The company has not undergone an audit for the first quarter report, indicating that the figures are unaudited[54] - The company has implemented new revenue and leasing standards starting in 2020, but these do not apply to the current financial report[53]